Posts Tagged: "Congressman Chaffetz"

IP and the 115th Congress: Meet the Republicans of the House IP Subcommittee

The House Judiciary Committee will set the agenda for any intellectual property legislative reforms that will arise over the next two years during the 115th Congress, and the Subcommittee on Courts, Intellectual Property, and the Internet will take the lead for the full House Judiciary Committee. Congressman Bob Goodlatte (R-VA) is once again Chair of the House Judiciary Committee, and in that role will continue to have tremendous influence on any intellectual property related matters… At the start of the 114th Congress, Congressman Darrell Issa was made Chair of the Subcommittee on Courts, Intellectual Property, and the Internet. Despite being an inventor himself, the bombastic Issa has aligned himself with Google and other Silicon Valley elites. Issa is not viewed as a friend of independent inventors, and instead lambasts patents trolls as often as he can. While no one likes a patent troll, Issa has taken the unusual step to equate patent trolls with all patent owners who enforce their patents.

Cruel and Unusual: Rumors swirl, still no answer on PTO Director

Fresh rumors surfaced late last night, however, suggesting that Commissioner for Patents Drew Hirshfeld is currently Acting Director of the USPTO. Two independent sources also told us that an internal candidate has been elevated to the position of Deputy Director of the USPTO, although it is not known whether that is on a permanent or temporary basis. It is believed that the Deputy Director of the USPTO is now Anthony Scardino, who was previously serving as Chief Financial Officer at the USPTO… Whatever the resolution of this matter is, this sad chapter in USPTO history has been grossly unfair to Michelle Lee. Either she is Director or she is not Director. Someone somewhere has to know the answer to this very simple, straightforward question, but no one with authority will comment.

Will More Regulation Create Cheaper Drugs?

The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full boil. Two recent actions turned up the heat to full blast. The response is often calls for more regulation, but ever increasing regulation benefits established players, which while inconvenienced, can afford to play the game. Start-ups can’t survive in endless oceans of red-tape that increase their costs while restricting market entry. Before rushing to impose more federal control, it might be wise to ask if government regulations inadvertently contribute to the problem.

House Judiciary approves Innovation Act despite clear lack of consensus

Dissent among members of Congress on the nature of the Innovation Act was evident from the opening remarks of the committee’s two ranking members. Congressman Bob Goodlatte (R-VA), the House Judiciary Committee Chairman and the Innovation Act’s major sponsor, stated that the Innovation Act would “ensure that the patent system lives up to its constitutional underpinnings” while targeting the abusive patent litigation which has been central to the debate on patent trolls. The ranking Democratic member of the committee, Congressman John Conyers (D-MI), said the bill was overly broad and yet it didn’t adequately address issues significant to this debate, including abusive demand letters and the ending of fee diversions from the U.S. Patent and Trademark Office’s budget.

IP and the 114th Congress: Meet the Republicans of the House IP Subcommittee

With respect to intellectual property it is the House Judiciary Committee that will set the agenda for any potential legislative reform over the next two years, with the Subcommittee on Courts, Intellectual Property, and the Internet leading the way. The often controversial Darrell Issa has lost his leadership position on the House Oversight Committee, but he has gained the gavel of this IP subcommittee. Few anticipate that he will easily be relegated to the back bench, so look for an active and bumpy ride over the next two years.